Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Files An 8-K Financial Statements and Exhibits
Item 9.01.
(d) Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press Release issued January 7, 2019 |
EXHIBIT INDEX
|
Exhibit Number |
Description |
| 99.1 | Press Release issued January 7, 2019 |
INTERCEPT PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 tv510502_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Intercept Announces NASH and PBC Program Updates Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis anticipated in Q1 2019 Phase 3 REVERSE trial of OCA in NASH patients with compensated cirrhosis projected to complete enrollment in 2019 Intercept acquires license to U.S. development and commercialization rights to pan-PPAR agonist bezafibrate with the goal of evaluating the potential for a fixed dose combination regimen with OCA for patients with primary biliary cholangitis (PBC) and other liver diseases NEW YORK,…
To view the full exhibit click here
About Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.